Active, Not Recruiting
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
NCT02304809
- Conditions
- Hematologic Cancers, Metastatic Cancers, Neoplasm Metastasis, +5 more
- Locations
-
- Tredaniel Paris, France